Neurogene (NGNE) Change in Receivables (2013 - 2015)
Neurogene's (NGNE) quarterly Change in Receivables came in at $12000.0 in Q4 2015, up 209.09% YoY from $3882.4 in Q4 2014, and up 122.64% on a QoQ basis from -$53000.0 in Q3 2015.
Powered by 
Analysis
Neurogene (NGNE) Change in Receivables (2013 - 2015) Analysis & Trends
Neurogene (NGNE) has 3 years of Change in Receivables data on file, last reported at $12000.0 in Q4 2015.
- Quarterly Change in Receivables rose 209.09% year-over-year to $12000.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was -$34000.0 (down 189.83% YoY) and the FY2015 annual result came in at -$34000.0, down 191.89% from the prior year.
- Change in Receivables improved to $12000.0 in Q4 2015, from -$53000.0 in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $43000.0 in Q3 2014 to a low of -$53000.0 in Q3 2015.
- A 3-year average of $270.83 and a median of -$2988.0 in 2013 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 22841.18% in 2014, down 358.06% in 2014.
- Tracing NGNE's Change in Receivables over 3 years: stood at -$6146.0 in 2013, then plunged by 78.98% to -$11000.0 in 2014, then surged by 209.09% to $12000.0 in 2015.
- The last three Change in Receivables figures came in at $12000.0 (Q4 2015), -$53000.0 (Q3 2015), and $15000.0 (Q2 2015), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -53.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 117.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 31.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Neurogene | 864.53 Mn | 864.53 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2015 | 12,000.00 |
| Sep 30, 2015 | -53,000.00 |
| Jun 30, 2015 | 15,000.00 |
| Mar 31, 2015 | -8,000.00 |
| Dec 31, 2014 | -11,000.00 |
| Sep 30, 2014 | 43,000.00 |
| Jun 30, 2014 | -33,151.00 |
| Dec 31, 2013 | -6,146.00 |
| Sep 30, 2013 | -7,469.00 |
| Jun 30, 2013 | 12,846.00 |
| Mar 31, 2013 | 170.00 |